LDVCX Performance — AXS FTSE Venture Capital Return Tracker Fund, Class C
Data updated: 2026-08-21
LDVCX returned −14.75% year to date and −19.36% over one year to Jun 2026. Annualised returns are +12.98% over 3 years and −3.94% over 5 years. The fund trailed its US Large Growth category average: $100 invested three years ago grew to $144, against $175 for the category, and to $81 over one year, against $117. Volatility over the past three years was 28.11% a year. In the 12 months to Jun 2026 the fund lost a net $17.5M, and assets reached $73.92M.
LDVCX Growth of $100
What $100 invested in AXS FTSE Venture Capital Return Tracker Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Large Growth category average over the same months.
| Period | LDVCX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $81 | $117 |
| 3 years (Jul 2023 – Jun 2026) | $144 | $175 |
| 5 years (Jul 2021 – Jun 2026) | $82 | $166 |
| Since data start (Oct 2020 – Jun 2026) | $109 | $207 |
LDVCX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | −14.75% |
| 1 year | −19.36% |
| 3 years (annualised) | +12.98% |
| 5 years (annualised) | −3.94% |
LDVCX Annual Returns
Calendar-year total returns of AXS FTSE Venture Capital Return Tracker Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | −14.75% |
| 2025 | +13.25% |
| 2024 | +25.38% |
| 2023 | +53.15% |
| 2022 | −56.21% |
| 2021 | +18.80% |
| 2020 (Oct–Dec) | +13.37% |
LDVCX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −8.9% | −9.4% | −5.6% | +5.5% | +13.3% | −8.5% | — | — | — | — | — | — |
| 2025 | +8.0% | −5.6% | −12.0% | +7.1% | +14.0% | +9.3% | −0.8% | −1.6% | +6.1% | +0.1% | −7.7% | −1.1% |
| 2024 | +6.1% | +6.8% | −1.6% | −11.3% | +2.8% | +11.7% | −4.1% | +3.8% | +3.7% | −0.5% | +13.8% | −5.6% |
| 2023 | +10.0% | −4.4% | +5.6% | +1.2% | +5.5% | +8.4% | +7.6% | −2.7% | −8.0% | −2.5% | +20.8% | +4.9% |
| 2022 | −20.7% | −13.7% | +3.4% | −24.5% | −5.1% | −12.1% | +15.6% | −6.0% | −14.7% | +9.4% | +5.7% | −8.2% |
| 2021 | −4.0% | +6.2% | +1.9% | +7.3% | −0.8% | +6.6% | +3.9% | +4.9% | −9.3% | +9.6% | −6.5% | −0.6% |
| 2020 | — | — | — | — | — | — | — | — | — | −5.6% | +13.5% | +5.8% |
LDVCX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 28.11%
- 3-year Sharpe ratio: 0.30 (vs 4.5% risk-free rate)
- Best month: +20.78% (Nov 2023)
- Worst month: −12.00% (Mar 2025)
LDVCX Fund Flows
Monthly money in and out of AXS FTSE Venture Capital Return Tracker Fund, from SEC Form N-PORT.
- 12-month net flow: −$17.5M
- 12-month gross sales (incl. reinvestments): $6.7M
- Sales ÷ redemptions: 0.28×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $336K | $1.4M | −$1.1M |
| May 2026 | $246K | $2.1M | −$1.9M |
| Apr 2026 | $465K | $1.7M | −$1.2M |
| Mar 2026 | $289K | $2.8M | −$2.5M |
| Feb 2026 | $496K | $2.7M | −$2.2M |
| Jan 2026 | $344K | $3.4M | −$3.0M |
| Dec 2025 | $164K | $1.1M | −$927K |
| Nov 2025 | $249K | $1.7M | −$1.5M |
| Oct 2025 | $492K | $1.9M | −$1.5M |
| Sep 2025 | $723K | $2.5M | −$1.8M |
| Aug 2025 | $530K | $1.5M | −$958K |
| Jul 2025 | $2.4M | $1.5M | $955K |
LDVCX Assets Under Management
Net assets of AXS FTSE Venture Capital Return Tracker Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $73.92M |
| 2026-03-31 | $71.23M |
| 2025-12-31 | $99.94M |
| 2025-09-30 | $113.17M |
| 2025-06-30 | $110.74M |
| 2025-03-31 | $86.19M |
| 2024-12-31 | $99.47M |
| 2024-09-30 | $96.96M |
| 2024-06-30 | $116.74M |
| 2024-03-31 | $130.95M |
| 2023-12-31 | $127.85M |
| 2023-09-30 | $104.93M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.